I thought I'd throw this out there for the interested parties of all persuasions.
In December 2016, Mesoblast entered into exclusive negotiations with Mallinckrodt Pharmaceuticals for a commercial and development partnership to develop product candidates for pediatric and adult aGVHD, outside of Japan and China. MSC-100-IV is marketed as TEMCELL HS Inj.® for acute GVHD in children and adults in Japan by Mesoblast’s licensee, JCR Pharmaceuticals.
In other words Mesoblast does not have a partner in Japan, they have a licensee. There is a difference, TiGenix is also a licensee.
I believe in general licensees use Mesoblast IP to develop products of their own, which Mesoblast can choose to license the use of the IP or not, in which case they cannot market said product or they open themselves up to litigation. Licensees generally either market product themselves or with their partners
Partners tend not develop product, though they could too, in which case they would need a license. There place is to push the product out to the market place, they may already have wide market penetration with other product lines or knowledge of various countries relevant legislation, e.g. the EU and then the member states own rules as pointed out by SI in latest webcast.
These are my interpretations of what I have read, please DYOR.
- Forums
- ASX - By Stock
- MSB
- MSB trading
MSB trading, page-535
-
- There are more pages in this discussion • 2,930 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B |
Open | High | Low | Value | Volume |
95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 29390 | 93.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.5¢ | 14089 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 24054 | 0.935 |
8 | 131583 | 0.930 |
4 | 65851 | 0.925 |
7 | 113334 | 0.920 |
9 | 97006 | 0.915 |
Price($) | Vol. | No. |
---|---|---|
0.945 | 1100 | 1 |
0.950 | 19026 | 2 |
0.955 | 27000 | 2 |
0.960 | 32869 | 2 |
0.965 | 35384 | 2 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online